FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2977431745> ?p ?o ?g. }

• W2977431745 abstract "The objective of this evidence-based analysis was to evaluate the clinical utility of serologic testing for celiac disease in asymptomatic individuals presenting with one of the non-gastrointestinal conditions evaluated in this report. The clinical utility was based on the effects of a gluten-free diet (GFD) on outcomes specific to each of these conditions. The prevalence of celiac disease in asymptomatic individuals and one of these non-gastrointestinal conditions was also evaluated.CELIAC DISEASE: Celiac disease is an autoimmune disease characterized by a chronic inflammatory state of the proximal small bowel mucosa accompanied by structural and functional changes. TECHNOLOGY UNDER EVALUATION: SEROLOGIC TESTS FOR CELIAC DISEASE: There are a number of serologic tests for celiac disease available. Serologic tests are automated with the exception of the anti-endomysial antibody test, which is more time-consuming and operator-dependent than the other tests.What is the prevalence of asymptomatic celiac disease in patients presenting with one of the non-gastrointestinal conditions evaluated?What is the effect of the gluten-free diet on condition-specific outcomes in patients with asymptomatic celiac disease presenting with one of the non-gastrointestinal conditions evaluated?What is the clinical utility of serologic testing for celiac disease in asymptomatic patients presenting with one of the non-gastrointestinal conditions evaluated? The clinical utility was defined as the impact of the GFD on disease specific outcomes.What is the risk of all-cause mortality and lymphoma in individuals with asymptomatic celiac disease?What is the budget impact of serologic testing for celiac disease in asymptomatic subjects presenting with one of the non-gastrointestinal conditions evaluated?The study population consisted of individuals with newly diagnosed celiac disease without any symptoms consistent with the disease presenting with one of the non-gastrointestinal conditions evaluated. When evaluating the risk of lymphoma and all-cause mortality, the study population consisted of asymptomatic individuals with a positive celiac disease serologic test and/or small bowel biopsy.Literature searches were performed for each disease/condition evaluated between December 2010 and March 2011 using OVID MEDLINE, the Cochrane Library, and the International Agency for Health Technology Assessment (INAHTA). No restrictions for start date of search were used. Abstracts were reviewed by a single reviewer and, for those studies meeting the eligibility criteria, full-text articles were obtained. Reference lists were also examined for any additional relevant studies not identified through the search. Articles with an unknown eligibility were reviewed with a second clinical epidemiologist and then a group of epidemiologists until consensus was established.Studies, systematic reviews, and meta-analyses that assessed the effects of a GFD in patients with newly diagnosed asymptomatic celiac disease presenting with one of the non-gastrointestinal conditions evaluated. If symptoms were not reported in the study but subjects were identified through screening for celiac disease the study was included.Studies, systematic reviews, and meta-analyses that assessed the prevalence of newly diagnosed asymptomatic celiac disease in patients with one of the non-gastrointestinal conditions evaluated. If symptoms were not reported in the study but subjects were identified through screening for celiac disease the study was included.Studies, systematic reviews, and meta-analyses that evaluated the risk of all-cause mortality or lymphoma in individuals with asymptomatic celiac disease.Sample size ≥ 10.Publications in English.Studies that retrospectively assessed the prevalence of asymptomatic celiac disease.Studies that reported the prevalence of one of the non-gastrointestinal conditions evaluated in subjects already diagnosed with celiac disease.Studies in individuals with one of the non-gastrointestinal conditions evaluated if the condition could be explained by other causes.Studies in subjects with celiac disease and symptoms consistent with the disease. If the study included individuals with and without symptoms consistent with celiac disease and their results were analysed separately, the results in individuals without symptoms were included in the analysis.Studies in which individuals did not report any symptoms consistent with celiac disease at study start but that either retrospectively reported the presence of such symptoms after following a GFD, or that previously presented with symptoms consistent with celiac disease.Study results published in letters to the editor or comments about other studies.Studies with a sample size ≥ 10, however, in which less than 10 patients were included in the analysis.The effects of a GFD on disease-specific outcomes for each condition evaluated in patients with asymptomatic celiac disease was assessed. The prevalence of asymptomatic celiac disease in patients presenting with one of the conditions evaluated was also assessed. RESULTS OF EVIDENCE-BASED ANALYSIS: Three eligible observational studies evaluated the effects of GFD on growth parameters in subjects with asymptomatic celiac disease and idiopathic short stature. Four eligible observational studies evaluated the effects of GFD on metabolic control in subjects with asymptomatic celiac disease and type 1 diabetes. Five eligible observational studies evaluated the risk of all-cause mortality and five eligible observational studies evaluated the risk of lymphoma in subjects with asymptomatic celiac disease. No eligible studies on the effects of the GFD for the other conditions evaluated were identified. Twenty-three eligible studies measured the prevalence of asymptomatic celiac disease in subjects presenting with one of the conditions evaluated. PREVALENCE OF CELIAC DISEASE IN ASYMPTOMATIC PATIENTS: The prevalence of celiac disease in asymptomatic patients presenting with one of the conditions evaluated was analysed. Most studies also included a control group that generally consisted of individuals randomly selected from the general population. Although there was a trend to a higher prevalence of asymptomatic celiac disease in individuals with the conditions evaluated compared to the controls, it only reached statistical significance in type 1 diabetes. No eligible prevalence studies were identified in patients with amenorrhea, delayed puberty, alopecia, and depression. THE EFFECTS OF A GLUTEN-FREE DIET ON DISEASE-SPECIFIC OUTCOMES IN PATIENTS WITH ASYMPTOMATIC CELIAC DISEASE: THE EFFECTS OF GFD ON METABOLIC CONTROL IN PATIENTS WITH ASYMPTOMATIC CELIAC DISEASE AND TYPE 1 DIABETES: The effects of a GFD on metabolic control (HbA1c, number of hypoglycemic episodes, and changes in insulin dosage) in subjects with asymptomatic celiac disease and type 1 diabetes were evaluated. One prospective case-control study reported an increase in HbA1c levels in cases with type 1 diabetes and asymptomatic celiac disease after the introduction of a GFD, however, the clinical significance of this change is unclear. Only one eligible retrospective case-control study evaluated the effects of a GFD on hypoglycemia episodes and since there were inadequate details in the study about both the ascertainment and severity of hypoglycemia episodes in both cases and controls, it is not possible to draw conclusions regarding the effects of a GFD on hypoglycemia episodes based on this study. One prospective case-control study did not show a statistically significant change in insulin dosage between cases with type 1 diabetes and asymptomatic celiac disease and controls with type 1 diabetes either before or after the introduction of a GFD. No eligible studies that evaluated the effects of a GFD on the long-term outcomes of type 1 diabetes such as cardiovascular or renal events in patients with asymptomatic celiac disease were identified. THE EFFECTS OF A GLUTEN-FREE DIET IN PATIENTS WITH IDIOPATHIC SHORT STATURE AND ASYMPTOMATIC CELIAC DISEASE: A total of 3 eligible studies were identified. All studies consisted of case series that compared growth parameters in subjects with asymptomatic celiac disease and idiopathic short stature before and after the celiac disease was diagnosed and the GFD was instituted. Most subjects included in the studies demonstrated an improvement in growth parameters. Compliance with the GFD was not reported in the studies. The results of the studies suggest an increase in growth velocity in pediatric patients with asymptomatic celiac disease and idiopathic short stature once a GFD is introduced. RISK OF LYMPHOMA IN PATIENTS WITH ASYMPTOMATIC CELIAC DISEASE: One retrospective cohort study evaluated the risk of lymphoma in patients with asymptomatic celiac disease. The authors concluded that the number of events identified was low during the long follow-up period and that the risk of overall malignancies was not increased among patients with asymptomatic celiac disease. RISK OF ASYMPTOMATIC CELIAC DISEASE IN PATIENTS WITH LYMPHOMA: Four case-control studies, one of which retrospective, evaluated the risk of asymptomatic celiac disease in patients newly diagnosed with lymphoma. One retrospective cohort study did not show an increase in the risk of lymphoma among subjects with asymptomatic celiac disease. Three prospective case-control studies did not find a statistically significant risk of asymptomatic celiac disease in patients with newly diagnosed lymphoma. (ABSTRACT TRUNCATED)" @default.
• W2977431745 created "2019-10-10" @default.
• W2977431745 creator A5084751005 @default.
• W2977431745 date "2011-01-01" @default.
• W2977431745 modified "2023-09-23" @default.
• W2977431745 title "Clinical utility of serologic testing for celiac disease in asymptomatic patients: an evidence-based analysis." @default.
• W2977431745 cites W1247968195 @default.
• W2977431745 cites W1955664038 @default.
• W2977431745 cites W1970679310 @default.
• W2977431745 cites W1974422110 @default.
• W2977431745 cites W1975400911 @default.
• W2977431745 cites W1980526118 @default.
• W2977431745 cites W1981680557 @default.
• W2977431745 cites W1987811453 @default.
• W2977431745 cites W1988699085 @default.
• W2977431745 cites W1988939129 @default.
• W2977431745 cites W1991535011 @default.
• W2977431745 cites W1993716459 @default.
• W2977431745 cites W1998974687 @default.
• W2977431745 cites W2005998473 @default.
• W2977431745 cites W2009580413 @default.
• W2977431745 cites W2009803666 @default.
• W2977431745 cites W2015046541 @default.
• W2977431745 cites W2026400537 @default.
• W2977431745 cites W2026443919 @default.
• W2977431745 cites W2034112915 @default.
• W2977431745 cites W2039134331 @default.
• W2977431745 cites W2048821674 @default.
• W2977431745 cites W2053236968 @default.
• W2977431745 cites W2053455656 @default.
• W2977431745 cites W2065194448 @default.
• W2977431745 cites W2070261338 @default.
• W2977431745 cites W2071043609 @default.
• W2977431745 cites W2071425986 @default.
• W2977431745 cites W2072365067 @default.
• W2977431745 cites W2081878625 @default.
• W2977431745 cites W2097723680 @default.
• W2977431745 cites W2098244992 @default.
• W2977431745 cites W2100294153 @default.
• W2977431745 cites W2106156983 @default.
• W2977431745 cites W2114518393 @default.
• W2977431745 cites W2128962458 @default.
• W2977431745 cites W2152460006 @default.
• W2977431745 cites W2153129600 @default.
• W2977431745 cites W2157504872 @default.
• W2977431745 cites W2165822344 @default.
• W2977431745 cites W2167705792 @default.
• W2977431745 cites W2169266069 @default.
• W2977431745 cites W2395202986 @default.
• W2977431745 cites W2410249953 @default.
• W2977431745 cites W3134084687 @default.
• W2977431745 cites W32550515 @default.
• W2977431745 cites W42526669 @default.
• W2977431745 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3377551" @default.
• W2977431745 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23074415" @default.
• W2977431745 hasPublicationYear "2011" @default.
• W2977431745 type Work @default.
• W2977431745 sameAs 2977431745 @default.
• W2977431745 citedByCount "2" @default.
• W2977431745 countsByYear W29774317452019 @default.
• W2977431745 countsByYear W29774317452022 @default.
• W2977431745 crossrefType "journal-article" @default.
• W2977431745 hasAuthorship W2977431745A5084751005 @default.
• W2977431745 hasConcept C126322002 @default.
• W2977431745 hasConcept C159654299 @default.
• W2977431745 hasConcept C203014093 @default.
• W2977431745 hasConcept C2777910003 @default.
• W2977431745 hasConcept C2779134260 @default.
• W2977431745 hasConcept C45189115 @default.
• W2977431745 hasConcept C71924100 @default.
• W2977431745 hasConceptScore W2977431745C126322002 @default.
• W2977431745 hasConceptScore W2977431745C159654299 @default.
• W2977431745 hasConceptScore W2977431745C203014093 @default.
• W2977431745 hasConceptScore W2977431745C2777910003 @default.
• W2977431745 hasConceptScore W2977431745C2779134260 @default.
• W2977431745 hasConceptScore W2977431745C45189115 @default.
• W2977431745 hasConceptScore W2977431745C71924100 @default.
• W2977431745 hasLocation W29774317451 @default.
• W2977431745 hasOpenAccess W2977431745 @default.
• W2977431745 hasPrimaryLocation W29774317451 @default.
• W2977431745 hasRelatedWork W13348360 @default.
• W2977431745 hasRelatedWork W1517657961 @default.
• W2977431745 hasRelatedWork W1838580850 @default.
• W2977431745 hasRelatedWork W1986245439 @default.
• W2977431745 hasRelatedWork W2030223244 @default.
• W2977431745 hasRelatedWork W2045760846 @default.
• W2977431745 hasRelatedWork W2067309350 @default.
• W2977431745 hasRelatedWork W2135895950 @default.
• W2977431745 hasRelatedWork W2171646510 @default.
• W2977431745 hasRelatedWork W2441361860 @default.
• W2977431745 hasRelatedWork W2469627646 @default.
• W2977431745 hasRelatedWork W2593775528 @default.
• W2977431745 hasRelatedWork W2791180965 @default.
• W2977431745 hasRelatedWork W2912515259 @default.
• W2977431745 hasRelatedWork W2999065152 @default.
• W2977431745 hasRelatedWork W3135275559 @default.
• W2977431745 hasRelatedWork W3135458487 @default.
• W2977431745 hasRelatedWork W3145961191 @default.
• W2977431745 hasRelatedWork W3152996641 @default.
• W2977431745 hasRelatedWork W3159163686 @default.

• next